Netherlands-based Qiagen has introduced new QIAseq Targeted cell-free DNA (cfDNA) Ultra Panels to advance cancer research.
Researchers studying cancer and other diseases can use the new panels to transform cfDNA liquid-biopsy samples into libraries ready for next-generation sequencing (NGS) within eight hours.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Part of the QIAseq Targeted DNA product portfolio, the new panels will help researchers identify somatic genetic variants in challenging detection scenarios with variant allele frequency as low as 0.1%.
The reliable and sensitive kit offers benefits such as improved chemistry, reduced enzymatic error rates and an optimised bioinformatics pipeline.
Qiagen life sciences business area head and senior vice-president Dr Thomas Schweins said: “Qiagen is dedicated to driving innovation in liquid biopsy technology to enhance cancer research and improve patient outcomes.
“With the launch of our QIAseq Targeted cfDNA Ultra Panels, researchers can now rapidly and accurately detect somatic genetic variants at low concentrations, providing a valuable tool for investigation of cancer and other diseases.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe QIAcuity digital polymerase chain reaction (PCR) system helps in the precise identification and quantification of DNA and RNA targets.
It will allow researchers to better analyse rare and difficult-to-detect targets for different applications.
Qiagen has also expanded its digital PCR portfolio with the introduction of new pan-cancer panels which will help study key cancer-related genes.
Expected to be available for customers later this year, the new assays will allow researchers to evaluate samples in multiplex reactions.
The panels can be used in different applications such as biomarker validation, orthogonal validation of NGS, drug monitoring, resistance monitoring and tumour characterisation.
